XML 40 R22.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | Revenues consisted of the following (in thousands):
|  |  | Year Ended December 31,
|  |  |  |  | 2021 |  | 2020 |  | 2019
Product revenues: |  |  |  |  |  |  |  |  |
Gross product revenues |  |  |  |  | $ | 1,452,913 |  |  | $ | 962,591 |  |  | $ | 957,621 |
Discounts and allowances |  |  |  |  | (375,657) |  |  | (221,041) |  |  | (197,671) |
Net product revenues |  |  |  |  | 1,077,256 |  |  | 741,550 |  |  | 759,950 |
Collaboration revenues: |  |  |  |  |  |  |  |  |
License revenues |  |  |  |  | 249,956 |  |  | 167,295 |  |  | 165,914 |
Collaboration services revenues |  |  |  |  | 107,758 |  |  | 78,693 |  |  | 41,911 |
Total collaboration revenues |  |  |  |  | 357,714 |  |  | 245,988 |  |  | 207,825 |
Total revenues |  |  |  |  | $ | 1,434,970 |  |  | $ | 987,538 |  |  | $ | 967,775 |
Net product revenues by product were as follows (in thousands):
|  |  | Year Ended December 31,
|  |  |  |  | 2021 |  | 2020 |  | 2019
CABOMETYX |  |  |  |  | $ | 1,054,050 |  |  | $ | 718,687 |  |  | $ | 733,421 |
COMETRIQ |  |  |  |  | 23,206 |  |  | 22,863 |  |  | 26,529 |
Net product revenues |  |  |  |  | $ | 1,077,256 |  |  | $ | 741,550 |  |  | $ | 759,950 |
Schedule of Concentration Risks | The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019
Ipsen Pharma SAS | 21 | % |  | 15 | % |  | 16 | %
Affiliates of CVS Health Corporation | 14 | % |  | 14 | % |  | 15 | %
Affiliates of McKesson Corporation | 14 | % |  | 12 | % |  | 12 | %
Affiliates of AmerisourceBergen Corporation | 14 | % |  | 11 | % |  | 11 | %
Affiliates of Optum Specialty Pharmacy | 8 | % |  | 11 | % |  | 13 | %
As of December 31, 2021 and 2020, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
| December 31,
| 2021 |  | 2020
Ipsen Pharma SAS | 50 | % |  | 23 | %
Affiliates of AmerisourceBergen Corporation | 11 | % |  | 11 | %
Affiliates of McKesson Corporation | 10 | % |  | 12 | %
Affiliates of CVS Health Corporation | 9 | % |  | 11 | %
Takeda Pharmaceutical Company Limited | 2 | % |  | 10 | %
Schedule of Revenues Disaggregated by Geographic Region | Total revenues by geographic region were as follows (in thousands):
|  |  | Year Ended December 31,
|  |  |  |  | 2021 |  | 2020 |  | 2019
U.S. |  |  |  |  | $ | 1,089,396 |  |  | $ | 752,890 |  |  | $ | 770,244 |
Europe |  |  |  |  | 302,073 |  |  | 151,631 |  |  | 152,771 |
Japan |  |  |  |  | 43,501 |  |  | 83,017 |  |  | 44,760 |
Total revenues |  |  |  |  | $ | 1,434,970 |  |  | $ | 987,538 |  |  | $ | 967,775 |
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
| Chargebacks, Discounts for Prompt Payment and Other |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  | Total
Balance at December 31, 2019 | $ | 7,514 |  |  | $ | 3,497 |  |  | $ | 15,222 |  |  | $ | 26,233 |
Provision related to sales made in: |  |  |  |  |  |  |
Current period | 146,537 |  |  | 16,162 |  |  | 58,049 |  |  | 220,748 |
Prior periods | 33 |  |  | (352) |  |  | 612 |  |  | 293 |
Payments and customer credits issued | (144,231) |  |  | (16,028) |  |  | (56,479) |  |  | (216,738) |
Balance at December 31, 2020 | 9,853 |  |  | 3,279 |  |  | 17,404 |  |  | 30,536 |
Provision related to sales made in: |  |  |  |  |  |  |
Current period | 243,119 |  |  | 30,728 |  |  | 100,361 |  |  | 374,208 |
Prior periods | (64) |  |  | (111) |  |  | 1,624 |  |  | 1,449 |
Payments and customer credits issued | (238,283) |  |  | (25,021) |  |  | (94,564) |  |  | (357,868) |
Balance at December 31, 2021 | $ | 14,625 |  |  | $ | 8,875 |  |  | $ | 24,825 |  |  | $ | 48,325 |
Schedule of Other Assets and Other Liabilities | Contract assets and liabilities were as follows (in thousands):
| December 31,
| 2021 |  | 2020
Contract assets(1) | $ | 1,665 |  |  | $ | — |
Contract liabilities: |  |  |
Current portion(2) | $ | 7,814 |  |  | $ | 1,790 |
Long-term portion(3) | 8,739 |  |  | 3,755 |
Total contract liabilities | $ | 16,553 |  |  | $ | 5,545 |
____________________ (1) Presented in other long-term assets in the accompanying Consolidated Balance Sheets. (2) Presented in other current liabilities in the accompanying Consolidated Balance Sheets. (3) Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration